IGF2BP1 and cancer: Previous research from our group implicated PRMT3 in oxaliplatin resistance through IGF2BP1 methylation,[13] with IGF2BP1 being implicated in chemoresistance across several cancer types.[24, 25, 26] We speculate IGF2BP1 may partly mediates chemoresistance in rectal cancer.